Jan 31, 2025 · Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases.

Novo Nordisk is the largest pharmaceutical company in Denmark. [14] Novo Nordisk's market capitalization exceeded the GDP of Denmark's domestic economy in 2023, and it is the highest valued company in Europe. [15]

2 days ago · Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes.

1 day ago · The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower growth this year. By Eshe Nelson Reporting from London Novo Nordisk ...

Apr 20, 2024 · In Kalundborg, population under 17,000, Novo Nordisk is making huge investments to increase production of its popular diabetes and weight-loss drugs, Ozempic and Wegovy.

Vi er en global lægemiddelvirksomhed, der blev grundlagt i 1923 med hovedkontor lige uden for København. Vores formål er at drive forandring for at bekæmpe diabetes og andre alvorlige kroniske sygdomme som svær overvægt og sjældne blodsygdomme og endokrine sygdomme.

Aug 28, 2023 · Novo Nordisk, the Danish company behind two popular obesity medications, is reaping huge profits and is now responsible for most of the country’s economic growth.

Dec 16, 2024 · Novo Nordisk is laying out 8.5 billion Danish kroner (about $1.2 billion) to establish a brand-new manufacturing plant in Odense, Denmark, where the company eventually plans to hire on...

Dec 16, 2024 · Novo Nordisk is planning a new investment, which marks the first time this millennium that the pharmaceutical company breaks ground in Denmark by establishing a new production site. A total of DKK 8.5 billion will be used for the new facility in Odense, Denmark.

Dec 16, 2024 · Danish drugmaker Novo Nordisk will invest 8.5 billion crowns ($1.20 billion) in a new facility in Odense, Denmark, for the production of rare disease drugs, it said on Monday.